Table 2 Clinical features of ACLF patients based on different outcomes
Parameters | Survivors (n = 30) | Non-survivors (n = 41) | P value |
|---|---|---|---|
Age (years) | 43.08 ± 9.7 | 46.10 ± 11.3 | 0.131 |
Gender (male/female) | 18/12 | 26/15 | 0.293 |
Alanine aminotransferase (U/L) | 444.9 ± 58.3 | 490.3 ± 66.2 | 0.614 |
Aspartate aminotransferase (U/L) | 501.3 ± 87.6 | 536.1 ± 74.6 | 0.592 |
Total bilirubin (μmol/l) | 332.8 ± 100.3 | 396.112 ± 87.3 | 0.007 |
Albumin (g/L) | 32.56 ± 5.4 | 30.9 ± 4.11 | 0.009 |
HBsAg positive (n) | 30 | 41 | – |
HBV DNA (log10 copies/mL) | 4.44 ± 1.25 | 4.16 ± 1.62 | 0.024 |
Creatinine (μmol/L) | 70.63 ± 26.9 | 79.65 ± 37.6 | 0.011 |
Prothrombin time (s) | 24.1 ± 6.6 | 26.4 ± 9.8 | 0.044 |
International normalized ratio | 2.31 ± 0.57 | 2.77 ± 0.55 | 0.056 |
IL-1β(pg/ml) | 1.49 ± 0.63 | 1.57 ± 0.87 | 0.78 |
IL-18(pg/m) | 287.33 ± 85.9 | 355.27 ± 100.14 | 0.007 |